| ALEC |
Alector, Inc. |
72%
|
Reciprocal relationship from ALEC graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ALEC graph: h pipeline. We initiated that reduction in force impacting approximately 25 … |
| ALT |
Altimmune, Inc. |
72%
|
Reciprocal relationship from ALT graph: h expected cash receipts from our equity transactions and research and development incentives, are sufficient to fund operations for at least a twelve-month pe… |
| ATAI |
AtaiBeckley Inc. |
72%
|
Reciprocal relationship from ATAI graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ATAI graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ATAI g… |
| BCYC |
Bicycle Therapeutics plc |
72%
|
Reciprocal relationship from BCYC graph: arch and development of our product candidates and preclinical programs, raising capital and providing general and administrative support for our operations. … |
| CMPS |
COMPASS Pathways plc |
72%
|
Reciprocal relationship from CMPS graph: tion in mental health. The Company is developing its investigational COMP360 psilocybin treatment through Phase 3 clinical trials in Europe and North America … |
| DYN |
Dyne Therapeutics, Inc. |
72%
|
Reciprocal relationship from DYN graph: nced central nervous system delivery and potential use in neurological indications. In preclinical studies, both conjugates achieved robust MAPT RNA knockdown … |
| ENGN |
enGene Therapeutics Inc. |
72%
|
Reciprocal relationship from ENGN graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ENGN graph: months ended January 31, 2025 to $8.9 million for the three months ended Jan… |
| HRTX |
Heron Therapeutics, Inc. |
72%
|
Reciprocal relationship from HRTX graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from HRTX graph: to register for resale 12.4 million shares of our common stock underlying th… |
| IRON |
Disc Medicine, Inc. |
72%
|
Reciprocal relationship from IRON graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from IRON graph: the agreement, the Company received an upfront payment of $ 0.2 million with… |
| KURA |
Kura Oncology, Inc. |
72%
|
Reciprocal relationship from KURA graph: cial to patients who are often elderly and on several concomitant medications. We initiated commercial sales of KOMZIFTI in the United States on November 21, … |
| MAZE |
Maze Therapeutics, Inc. |
72%
|
Reciprocal relationship from MAZE graph: ment of our Maze Compass platform, or our Compass platform, planned preclinical studies, IND filings and clinical trials for future therapeutic candidates. We… |
| MDGL |
Madrigal Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from MDGL graph: h and development is very expensive, time-consuming and difficult to design and implement and involves uncertain outcomes. Furthermore, the results of preclin… |
| MLTX |
MoonLake Immunotherapeutics |
72%
|
Reciprocal relationship from MLTX graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from MLTX graph: e cash, cash equivalents, and short-term marketable securities will be suffi… |
| OBIO |
Orchestra BioMed Holdings, Inc. |
72%
|
Reciprocal relationship from OBIO graph: ares”), at an exercise price equal to $ 3.67 per share. The exercise price of the Ligand Warrants and the number of Ligand Warrant Shares issuable upon exerci… |
| PHAT |
Phathom Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from PHAT graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from PHAT graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from PHAT g… |
| PHGE |
BiomX Inc. |
72%
|
Reciprocal relationship from PHGE graph: SPA, we agreed to issue and sell, in a private placement transaction, an aggregate of 3,300 shares of our newly created Series Y Convertible Preferred Stock, … |
| RCUS |
Arcus Biosciences, Inc. |
72%
|
Reciprocal relationship from RCUS graph: non-public information and for complying with our disclosure obligations under the Regulation FD. Such disclosures will be included on the company’s website u… |
| REPL |
Replimune Group, Inc. |
72%
|
Reciprocal relationship from REPL graph: rkets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. A weak or… |
| SENS |
Senseonics Holdings, Inc. |
72%
|
Reciprocal relationship from SENS graph: ing our products or those of our competitors; ● Ascensia’s ability to increase sales of Eversense and to commercialize and sell our future products, and the n… |
| SGHT |
Sight Sciences, Inc. |
72%
|
Reciprocal relationship from SGHT graph: in our inventory balance. The non-cash charges primarily consisted of $4.2 million related to stock-based compensation expense, $0.2 million of accretion of d… |
| SVRA |
Savara Inc. |
72%
|
Reciprocal relationship from SVRA graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from SVRA graph: we may establish; • the number of clinical and nonclinical studies necessary… |
| TGTX |
TG Therapeutics, Inc. |
72%
|
Reciprocal relationship from TGTX graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from TGTX g… |
| VRDN |
Viridian Therapeutics, Inc. |
72%
|
Reciprocal relationship from VRDN graph: Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q, we may require significant additional capital earlier than we currently expect under our presen… |
